|
|
||||||||
The Annals of Thoracic Surgery, Vol 41, 193-199, Copyright © 1986 by The Society of Thoracic Surgeons
JK Kirklin, DE Chenoweth, DC Naftel, EH Blackstone, JW Kirklin, DD Bitran, JG Curd, JG Reves and PN Samuelson
Nineteen patients were prospectively selected and studied before and after
the administration of protamine sulfate following cardiopulmonary bypass
(CPB). After protamine administration, C3a, C4a, and C4d were elevated; the
peak levels of C3a and C4a were in samples taken 10 minutes after protamine
administration while those of C4d were in those obtained at 5 hours. Only
C3a was elevated after CPB and before protamine administration. In vitro,
only the combination of protamine sulfate and heparin, and neither alone,
resulted in increased C3a and C4a. Administration of protamine was
associated with small and transient decreases in total white blood cells,
granulocytes, and platelets, and with small and transient reductions in
systemic and pulmonary arterial and left and right atrial pressures.
Systemic vascular resistance fell (p = 0.07), and pulmonary vascular
resistance rose but the change could be due to chance (p = 0.29). These
data and those reported by others support the inference that complement
activation occurs during CPB by the alternative pathway and again during
protamine administration by the classic pathway; and that this accompanies
a whole-body inflammatory reaction with blood cell and hemodynamic changes
which, when extreme, could result in a severe hemodynamic derangement.
ARTICLES
Effects of protamine administration after cardiopulmonary bypass on complement, blood elements, and the hemodynamic state
This article has been cited by other articles:
![]() |
B. Marcheix, M. Carrier, C. Martel, M. Cossette, M. Pellerin, D. Bouchard, and L. P. Perrault Effect of Pericardial Blood Processing on Postoperative Inflammation and the Complement Pathways Ann. Thorac. Surg., February 1, 2008; 85(2): 530 - 535. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Hammon Extracorporeal Circulation: The Response of Humoral and Cellular Elements of Blood to Extracorporeal Circulation Card. Surg. Adult, January 1, 2008; 3(2008): 370 - 389. [Full Text] |
||||
![]() |
S. Gunaydin, K. McCusker, V. Vijay, S. Isbir, T. Sari, M. A. Onur, A. Gurpinar, A. Sezgin, M. F Sargon, T. Tezcaner, et al. Comparison of polymethoxyethylacrylate-coated circuits with leukocyte filtration and reduced heparinization protocol on heparin-bonded circuits in different risk cohorts Perfusion, November 1, 2006; 21(6): 329 - 342. [Abstract] [PDF] |
||||
![]() |
D. J. Kozik and J. S. Tweddell Characterizing the Inflammatory Response to Cardiopulmonary Bypass in Children Ann. Thorac. Surg., June 1, 2006; 81(6): S2347 - S2354. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Quaniers, J. Leruth, A. Albert, R. R. Limet, and J.-O. Defraigne Comparison of inflammatory responses after off-pump and on-pump coronary surgery using surface modifying additives circuit. Ann. Thorac. Surg., May 1, 2006; 81(5): 1683 - 1690. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ikuta, H. Fujii, T. Shibata, K. Hattori, H. Hirai, H. Kumano, and S. Suehiro A new poly-2-methoxyethylacrylate-coated cardiopulmonary bypass circuit possesses superior platelet preservation and inflammatory suppression efficacy Ann. Thorac. Surg., May 1, 2004; 77(5): 1678 - 1683. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. A. Seifert, D. R. Jobes, T. Ten Have, S. E. Kimmel, L. M. Montenegro, J. M. Steven, S. C. Nicolson, and B. L. Strom Adverse Events After Protamine Administration Following Cardiopulmonary Bypass in Infants and Children Anesth. Analg., August 1, 2003; 97(2): 383 - 389. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. H. Edmunds Jr. and R. W. Colman Extracorporeal Circulation: Thrombosis and Bleeding Card. Surg. Adult, January 1, 2003; 2(2003): 338 - 348. [Full Text] |
||||
![]() |
P. Menasche and L. H. Edmunds Jr. Extracorporeal Circulation: The Inflammatory Response Card. Surg. Adult, January 1, 2003; 2(2003): 349 - 360. [Full Text] |
||||
![]() |
C. Baufreton, J. L. de Brux, P. Binuani, J.-J. Corbeau, J. B. Subayi, J. C. Daniel, and P. Treanor A combined approach for improving cardiopulmonary bypass in coronary artery surgery: a pilot study Perfusion, December 1, 2002; 17(6): 407 - 413. [Abstract] [PDF] |
||||
![]() |
F. Viaro, M. B. Dalio, and P. R. B. Evora MD Catastrophic Cardiovascular Adverse Reactions to Protamine Are Nitric Oxide/Cyclic Guanosine Monophosphate Dependent and Endothelium Mediated* : Should Methylene Blue Be the Treatment of Choice? Chest, September 1, 2002; 122(3): 1061 - 1066. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Undar, H. C. Eichstaedt, F. J. Clubb Jr, M. Fung, M. Lu, J. E. Bigley, W. K. Vaughn, and C. D. Fraser Jr Novel anti-factor D monoclonal antibody inhibits complement and leukocyte activation in a baboon model of cardiopulmonary bypass Ann. Thorac. Surg., August 1, 2002; 74(2): 355 - 362. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Herzenberg, J. S. Gill, O. Djurdjev, and A. B. Magil C4d Deposition in Acute Rejection: An Independent Long-Term Prognostic Factor J. Am. Soc. Nephrol., January 1, 2002; 13(1): 234 - 241. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. A. Hennein Inflammation After Cardiopulmonary Bypass: Therapy for the Postpump Syndrome Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2001; 5(3): 236 - 255. [Abstract] [PDF] |
||||
![]() |
M. Fung, P. G. Loubser, A. Undar, M. Mueller, C. Sun, W. N. Sun, W. K. Vaughn, and C. D. Fraser Jr Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuits J. Thorac. Cardiovasc. Surg., July 1, 2001; 122(1): 113 - 122. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Codispoti, C. A. Ludlam, D. Simpson, and P. S. Mankad Individualized heparin and protamine management in infants and children undergoing cardiac operations Ann. Thorac. Surg., March 1, 2001; 71(3): 922 - 927. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Milot, J. Perron, Y. Lacasse, L. Letourneau, P. C. Cartier, and F. Maltais Incidence and Predictors of ARDS After Cardiac Surgery Chest, March 1, 2001; 119(3): 884 - 888. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. B. Zwischenberger, W. Tao, D. J. Deyo, R. A. Vertrees, S. K. Alpard, and G. Shulman Safety and efficacy of a heparin removal device: a prospective randomized preclinical outcomes study Ann. Thorac. Surg., January 1, 2001; 71(1): 270 - 277. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Despotis and L. T. Goodnough Management approaches to platelet-related microvascular bleeding in cardiothoracic surgery Ann. Thorac. Surg., August 1, 2000; 70(2): S20 - 32. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Codispoti and P. S Mankad Management of anticoagulation and its reversal during paediatric cardiopulmonary bypass: a review of current UK practice Perfusion, May 1, 2000; 15(3): 191 - 201. [Abstract] [PDF] |
||||
![]() |
Y. J. Gu, M. A. Mariani, P. W. Boonstra, J. G. Grandjean, and W. v. Oeveren Complement Activation in Coronary Artery Bypass Grafting Patients Without Cardiopulmonary Bypass: The Role of Tissue Injury by Surgical Incision Chest, October 1, 1999; 116(4): 892 - 898. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Kimmel, M. A. Sekeres, J. A. Berlin, N. Ellison, V. J. DiSesa, and B. L. Strom Risk factors for clinically important adverse events after protamine administration following cardiopulmonary bypass J. Am. Coll. Cardiol., December 1, 1998; 32(7): 1916 - 1922. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Weerasinghe and K. M. Taylor The platelet in cardiopulmonary bypass Ann. Thorac. Surg., December 1, 1998; 66(6): 2145 - 2152. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tofukuji, G. L. Stahl, A. Agah, C. Metais, M. Simons, and F. W. Sellke ANTI-C5A MONOCLONAL ANTIBODY REDUCES CARDIOPULMONARY BYPASS AND CARDIOPLEGIA-INDUCED CORONARY ENDOTHELIAL DYSFUNCTION J. Thorac. Cardiovasc. Surg., December 1, 1998; 116(6): 1060 - 1069. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Galea, N. Rebuck, A. Finn, A. Manche, and N. Moat Expression of soluble endothelial adhesion molecules in clinical cardiopulmonary bypass Perfusion, September 1, 1998; 13(5): 314 - 321. [Abstract] [PDF] |
||||
![]() |
R de Vroege, P M. Rutten, C Kalkman, T A Out, P G. Jansen, L Eijsman, B J. de Mol, and C R. Wildevuur Biocompatibility of three different membrane oxygenators: effects on complement, neutrophil and monocyte activation Perfusion, December 1, 1997; 12(6): 369 - 375. [Abstract] [PDF] |
||||
![]() |
P. Bruins, H. t. Velthuis, A. P. Yazdanbakhsh, P. G. M. Jansen, F. W. J. van Hardevelt, E. M. F. H. de Beaumont, C. R. H. Wildevuur, L. Eijsman, A. Trouwborst, and C. E. Hack Activation of the Complement System During and After Cardiopulmonary Bypass Surgery : Postsurgery Activation Involves C-Reactive Protein and Is Associated With Postoperative Arrhythmia Circulation, November 18, 1997; 96(10): 3542 - 3548. [Abstract] [Full Text] |
||||
![]() |
K. A. Shastri, G. L. Logue, M. P. Stern, S. Rehman, and S. Raza COMPLEMENT ACTIVATION BY HEPARIN-PROTAMINE COMPLEXES DURING CARDIOPULMONARY BYPASS: EFFECT OF C4A NULL ALLELE J. Thorac. Cardiovasc. Surg., September 1, 1997; 114(3): 482 - 488. [Abstract] [Full Text] |
||||
![]() |
A. Belboul and N. Al-Khaja The effect of protamine on the epicardial microflow and the graft flow in open-heart surgery Perfusion, March 1, 1997; 12(2): 99 - 106. [Abstract] [PDF] |
||||
![]() |
S. Bannan, A. Danby, D. Cowan, S. Ashraf, and P. G. Martin Low Heparinization With Heparin-Bonded Bypass Circuits: Is It a Safe Strategy? Ann. Thorac. Surg., March 1, 1997; 63(3): 663 - 668. [Abstract] [Full Text] |
||||
![]() |
H E Hogevold, O Moen, E Fosse, P Venge, J Braten, C Andersson, and T Lyberg Effects of heparin coating on the expression of CD11b, CD11c and CD62L by leucocytes in extracorporeal circulation in vitro Perfusion, January 1, 1997; 12(1): 9 - 20. [Abstract] [PDF] |
||||
![]() |
S.-J. O, M. H. Cox, R. Mukherjee, M. J. Clair, F. A. Crawford Jr, and F. G. Spinale Direct and Interactive Effects of Cardioplegic Arrest and Protamine on Myocyte Contractility Ann. Thorac. Surg., August 1, 1996; 62(2): 489 - 494. [Abstract] [Full Text] |
||||
![]() |
D. D. Muehrcke, P. M. McCarthy, K. Kottke-Marchant, H. Harasaki, J. Pierre-Yared, J. A. Borsh, D. A. Ogella, and D. M. Cosgrove BIOCOMPATIBILITY OF HEPARIN-COATED EXTRACORPOREAL BYPASS CIRCUITS: A RANDOMIZED, MASKED CLINICAL TRIAL J. Thorac. Cardiovasc. Surg., August 1, 1996; 112(2): 472 - 483. [Abstract] [Full Text] |
||||
![]() |
G. V. Raikar, K. Hisamochi, B.-L. N. Raikar, and H. V. Schaff NITRIC OXIDE INHIBITION ATTENUATES SYSTEMIC HYPOTENSION PRODUCED BY PROTAMINE J. Thorac. Cardiovasc. Surg., June 1, 1996; 111(6): 1240 - 1247. [Abstract] [Full Text] |
||||
![]() |
O. Moen, E. Fosse, J. Braten, C. Andersson, K. Hogasen, T. Mollnes, P. Venge, and P. Kierulf Differences in blood activation related to roller/centrifugal pumps and heparin coated/uncoated surfaces in a cardiopulmonary bypass model circuit Perfusion, March 1, 1996; 11(2): 113 - 123. [Abstract] [PDF] |
||||
![]() |
R. C. Gorman, N. P. Ziats, A. K. Rao, N. Gikakis, L. Sun, M. M. H. Khan, N. Stenach, S. Sapatnekar, V. Chouhan, J. H. Gorman III, et al. SURFACE-BOUND HEPARIN FAILS TO REDUCE THROMBIN FORMATION DURING CLINICAL CARDIOPULMONARY BYPASS J. Thorac. Cardiovasc. Surg., January 1, 1996; 111(1): 1 - 12. [Abstract] [Full Text] |
||||
![]() |
R. B. Hird, T. W. Wakefield, R. Mukherjee, B. U. Jones, F. A. Crawford, P. C. Andrews, J. C. Stanley, and F. G. Spinale Direct Effects of Protamine Sulfate on Myocyte Contractile Processes : Cellular and Molecular Mechanisms Circulation, November 1, 1995; 92(9): 433 - 446. [Abstract] [Full Text] |
||||
![]() |
E. Ovrum, F. Brosstad, E. Am Holen, G. Tangen, and M. Abdelnoor Effects on Coagulation and Fibrinolysis With Reduced Versus Full Systemic Heparinization and Heparin-Coated Cardiopulmonary Bypass Circulation, November 1, 1995; 92(9): 2579 - 2584. [Abstract] [Full Text] |
||||
![]() |
P. G. M. Jansen, H. t. Velthuis, R. A. J. M. Huybregts, R. Paulus, E. R. Bulder, H. I. van der Spoel, P. D. Bezemer, E. H. Slaats, L. Eijsman, and C. R. H. Wildevuur Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits J. Thorac. Cardiovasc. Surg., September 1, 1995; 110(3): 829 - 834. [Abstract] [Full Text] |
||||
![]() |
E. Ovrum, E. A. Holen, G. Tangen, F. Brosstad, M. Abdelnoor, M.-A. L. Ringdal, R. Oystese, and R. Istad Completely Heparinized Cardiopulmonary Bypass and Reduced Systemic Heparin: Clinical and Hemostatic Effects Ann. Thorac. Surg., August 1, 1995; 60(2): 365 - 371. [Abstract] [Full Text] |
||||
![]() |
P. R. B. Evora, P. J. Pearson, and H. V. Schaff Protamine Induces Endothelium-Dependent Vasodilatation of the Pulmonary Artery Ann. Thorac. Surg., August 1, 1995; 60(2): 405 - 410. [Abstract] [Full Text] |
||||
![]() |
D. R. Jobes, G. L. Aitken, and G. W. Shaffer Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion patients undergoing primary cardiac operations J. Thorac. Cardiovasc. Surg., July 1, 1995; 110(1): 36 - 45. [Abstract] [Full Text] |
||||
![]() |
J. P. A. M. Schonberger, P. A. M. Everts, and J. J. Hoffmann Systemic Blood Activation With Open and Closed Venous Reservoirs Ann. Thorac. Surg., June 1, 1995; 59(6): 1549 - 1555. [Abstract] [Full Text] |
||||
![]() |
A. Bernabei, T. E Maione, M. A. Kowalska, Z. Yan, S. Niewiarowski, and L. H. Edmunds Jr. Reversal of heparin anticoagulation by recombinant platelet factor 4 and protamine sulfate in baboons during cardiopulmonary bypass J. Thorac. Cardiovasc. Surg., April 1, 1995; 109(4): 765 - 771. [Abstract] [Full Text] |
||||
![]() |
M. Friedman, R. G. Johnson, S. Y. Wang, H. B. Dai, R. L. Thurer, R. M. Weintraub, and F. W. Sellke Pulmonary microvascular responses to protamine and histamineEffects of cardiopulmonary bypass J. Thorac. Cardiovasc. Surg., December 1, 1994; 108(6): 1092 - 1099. [Abstract] [Full Text] |
||||
![]() |
R. B. Hird, F. G. Spinale, K. W. Hewett, R. Mukherjee, and F. A. Crawford The direct effects of protamine sulfate on myocyte contractile processes J. Thorac. Cardiovasc. Surg., December 1, 1994; 108(6): 1100 - 1114. [Abstract] [Full Text] |
||||
![]() |
R. D. Williams, M. N. D'Ambra, T. E. Maione, K. E. Lynch, and D. F. Keene Recombinant platelet factor 4 reversal of heparin in human cardiopulmonary bypass blood J. Thorac. Cardiovasc. Surg., November 1, 1994; 108(5): 975 - 983. [Abstract] [Full Text] |
||||
![]() |
D. S. Kucukaksu, S. F. Katircioglu, G. Saydam, M. Bozdayi, B. Mavitas, O. Tasdemir, and K. Bayazit Beneficial Effects of Prostacyclin on Pulmonary Function During Heparin Reversal with Protamine Vascular and Endovascular Surgery, May 1, 1993; 27(4): 264 - 267. [Abstract] [PDF] |
||||
![]() |
C. Aren Review article : Heparin and protamine during cardiac surgery Perfusion, July 1, 1989; 4(3): 171 - 181. [PDF] |
||||
![]() |
A T. Pezzella, A. Ascioti, and P. Ricardi Noncardiogenic pulmonary oedema following cardiopulmonary bypass: report of two cases and review of the literature Perfusion, January 1, 1988; 3(1): 21 - 28. [Abstract] [PDF] |
||||
![]() |
W. van Oeveren and C. Wildevuur Review article : Blood compatibility of cardiopulmonary bypass circuits Perfusion, October 1, 1987; 2(4): 237 - 244. [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |